Health TidingsEisai and Biogen Secure Priority Review in China for Subcutaneous LEQEMBI Eisai and Biogen Secure Priority Review in China for Subcutaneous LEQEMBI Read Post »
Health TidingsSanofi’s Rilzabrutinib Gains FDA Breakthrough Therapy Designation, Ja... Sanofi’s Rilzabrutinib Gains FDA Breakthrough Therapy Designation, Ja... Read Post »
Clinical TrailsJohnson & Johnson Reports Results from OMNY-AF Study in A-Fib Johnson & Johnson Reports Results from OMNY-AF Study in A-Fib Read Post »
New Drug ApprovalGSK’s Nucala Secures European Approval for Eosinophilic COPD GSK’s Nucala Secures European Approval for Eosinophilic COPD Read Post »
Food Health TidingsUK Probes 36 Infant Illness Reports Linked to Recalled Infant Formula UK Probes 36 Infant Illness Reports Linked to Recalled Infant Formula Read Post »
Health TidingsFrom Launch to Halt: Hims & Hers’ Semaglutide Reversal From Launch to Halt: Hims & Hers’ Semaglutide Reversal Read Post »
Clinical TrailsFDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label FDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label Read Post »
Health TidingsPfizer Backs TrumpRx, Reduce Drug Prices in the U.S. Pfizer Backs TrumpRx, Reduce Drug Prices in the U.S. Read Post »
Health TidingsFibrobiologics Fetches Canadian Patent for Cachexia in Chronic Diseases Fibrobiologics Fetches Canadian Patent for Cachexia in Chronic Diseases Read Post »
Health TidingsTrumpRx.gov Goes Live, Drug Pricing and Policy in One Platform TrumpRx.gov Goes Live, Drug Pricing and Policy in One Platform Read Post »
Clinical TrailsDenali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Denali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Read Post »
Clinical TrailsPfizer’s HYMPAVZI Secures FDA Priority Review for Kids Pfizer’s HYMPAVZI Secures FDA Priority Review for Kids Read Post »
Health TidingsEisai and Biogen Report Growing Real-World Use of Leqembi in Early Alzheime... Eisai and Biogen Report Growing Real-World Use of Leqembi in Early Alzheime... Read Post »
Health TidingsFDA Takes Aim at Non-Approved Compounded GLP-1 Drugs FDA Takes Aim at Non-Approved Compounded GLP-1 Drugs Read Post »
Drugs Safety AlertFDA Revises Capecitabine and 5-FU Labels to Address DPD Deficiency Risk FDA Revises Capecitabine and 5-FU Labels to Address DPD Deficiency Risk Read Post »
Clinical TrailsFDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... FDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... Read Post »
Health TidingsNovo Nordisk Accuses Hims & Hers of Illegal Semaglutide Compounding, Ci... Novo Nordisk Accuses Hims & Hers of Illegal Semaglutide Compounding, Ci... Read Post »
Clinical TrailsBayer’s Asundexian Cuts Stroke Risk 26% in Phase III Bayer’s Asundexian Cuts Stroke Risk 26% in Phase III Read Post »
Health TidingsBMS and J&J Rethink Anticoagulation with Factor Xia BMS and J&J Rethink Anticoagulation with Factor Xia Read Post »
Health TidingsSimcere Doses First Patient in Anti-Stroke SIM0811 Trial Simcere Doses First Patient in Anti-Stroke SIM0811 Trial Read Post »
Food Policy & AcquisitionsNo to Artificial Colors, Yes to Natural Alternatives: What the New FDA Poli... No to Artificial Colors, Yes to Natural Alternatives: What the New FDA Poli... Read Post »
New Drug ApprovalFDA Approves VYBRIQUE as First Oral Film for Erectile Dysfunction FDA Approves VYBRIQUE as First Oral Film for Erectile Dysfunction Read Post »
New Drug ApprovalAbbVie Seeks FDA, EMA Approval of RINVOQ in Vitiligo AbbVie Seeks FDA, EMA Approval of RINVOQ in Vitiligo Read Post »
Health TidingsEli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Eli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Read Post »
Clinical TrailsUCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... UCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... Read Post »
Clinical TrailsFDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease FDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease Read Post »
Clinical TrailsAstellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Astellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Read Post »
Clinical TrailsImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma ImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma Read Post »
Health TidingsValneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Valneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Read Post »
ResearchJohnson & Johnson Calls Out Surgeon Mental Health Crisis Johnson & Johnson Calls Out Surgeon Mental Health Crisis Read Post »
Health TidingsNovo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Novo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Read Post »
Clinical TrailsNovo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Novo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Read Post »
Health TidingsSPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher SPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher Read Post »
New Drug ApprovalBayer’s Nubeqa Approved for mHSPC in China Bayer’s Nubeqa Approved for mHSPC in China Read Post »
Clinical TrailsPfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Pfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Read Post »
Health TidingsAstraZeneca Faces FDA Delay for At-Home Saphnelo SC in SLE AstraZeneca Faces FDA Delay for At-Home Saphnelo SC in SLE Read Post »
Clinical TrailsJohnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Johnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Read Post »
Health TidingsFDA Issues Complete Response Letter for Anaphylm Sublingual Epinephrine Fil... FDA Issues Complete Response Letter for Anaphylm Sublingual Epinephrine Fil... Read Post »
Clinical TrailsPositive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Positive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Read Post »
Policy & AcquisitionsIllumina Completes Acquisition of SomaLogic Illumina Completes Acquisition of SomaLogic Read Post »
New Drug ApprovalImfinzi Boosts Survival in Gastric Cancer, Gains CHMP Endorsement Imfinzi Boosts Survival in Gastric Cancer, Gains CHMP Endorsement Read Post »
Clinical TrailsLundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Lundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Read Post »
Health TidingsFDA Issues CRL for Pharming’s Joenja in Pediatric APDS Patients FDA Issues CRL for Pharming’s Joenja in Pediatric APDS Patients Read Post »
New Drug ApprovalCHMP Backs Rezurock for Chronic GVHD After Re-Examination CHMP Backs Rezurock for Chronic GVHD After Re-Examination Read Post »
New Drug ApprovalIncyte’s Zynyz Wins Positive CHMP Opinion in Advanced Anal Cancer Incyte’s Zynyz Wins Positive CHMP Opinion in Advanced Anal Cancer Read Post »
ResearchMigraine Attacks Disrupt Relationships, AbbVie Report Migraine Attacks Disrupt Relationships, AbbVie Report Read Post »
New Drug ApprovalEMA CHMP Recommends Bayer’s Finerenone for Heart Failure with LVEF â‰... EMA CHMP Recommends Bayer’s Finerenone for Heart Failure with LVEF â‰... Read Post »
New Drug ApprovalJ&J Scores CHMP Nod for AKEEGA in High-Risk Prostate Cancer J&J Scores CHMP Nod for AKEEGA in High-Risk Prostate Cancer Read Post »
New Drug ApprovalFDA Approves Tenpoint’s YUVEZZI Eye Drop for Presbyopia Treatment FDA Approves Tenpoint’s YUVEZZI Eye Drop for Presbyopia Treatment Read Post »
Clinical TrailsUltragenyx Resubmits BLA for UX111 Gene Therapy in Sanfilippo Syndrome Type... Ultragenyx Resubmits BLA for UX111 Gene Therapy in Sanfilippo Syndrome Type... Read Post »
